OBJECTIVE

To assess the effectiveness and safety of erenumab in real-life study.

MATERIAL AND METHODS

33 patients with episodic and chronic migraine (30 females, mean age 39.2±9.2, 3 males, mean age — 49.3±7.6) received erenumab 70 mg for each 3 months. Patients achieved a 50% reduction in the number of days with headache, pain intensity, duration, the number of days of acute medication use, effect on daily activity (HIT-6), side effects, neuropsychological testing (Beck Depression scale, Spielberger-Khanin questionnaire, Hospital Depression and Anxiety Scale) were assessed.

RESULTS

During the first month of therapy, a 50% decrease in headache days was observed in 48% of patients, during the second — in 53% of patients, during the third — in 51.5% of patients (p<0.001), a reduce in pain intensity, HIT-6 score, duration of migraine attack was observed (p<0.005). A decrease in situational anxiety was revealed (Spielberger—Khanin questionnaire, p=0.02), but not depression. There was a decrease in the consumption of triptans (p<0.0005) and other analgesics (p=0.0018). 1 patient noted transient constipation.

CONCLUSION

The effectiveness and safety of erenumab in the outpatient practice is shown.